CoreValve Evolut R TAVR 26mm via Percutaneous Femoral Access

Medstream360 members only

To view this video and learn more about the procedure please Login or Register.
Membership is free!

The Mount Sinai Hospital

1468 Madison Avenue, New York,
New York 10029

CoreValve Evolut R TAVR 26mm via Percutaneous Femoral Access

Core valve TAVR

83-year-old female presented with worsening dyspnea on exertion– NYHA class III and fatigue, with a history of hypertension, Atrial Flutter s/p PPM, moderate COPD, Septal Hypertrophy s/p ablation, kyphosis, and Rt. Breast CA s/p radiation. TTE revealed severe AS, peak/mean aortic gradient = 79/49 mmHg, AVA = 0.5 sq cm, aortic peak velocity = 4.4 m/sec and LVEF 57%. CT angio showed minimum diameters of 0.8 x 0.9 cm for right and 0.8 x 0.9 cm for left common femoral arteries and aortic annulus of 2.4 X 1.8 cm (average 2.1 cm). The STS risk mortality is 5.8% and the Logistic Euroscore mortality is 14.7%. Patient was determined to be high risk for surgical AVR due to COPD and frailty. Patient is now planned for Evolut-R CoreValve TAVR (26mm) via percutaneous femoral access under conscious sedation.

download

Case Presentation

close

Lorem ipsum dolor sit amet consectetur adipisicing elit. A, dignissimos?